Biliary-derived hepatocytes in chronic liver injury

Citation for published version:
https://doi.org/10.1016/j.jhep.2019.03.015

Digital Object Identifier (DOI):
10.1016/j.jhep.2019.03.015

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published in:
Journal of Hepatology

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and/or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Title: Biliary-derived hepatocytes in chronic liver injury: bringing new troops to the battlefield?

Article Type: Invited Editorial

Section/Category: Basic liver injury and regeneration

Corresponding Author: Professor Stuart Forbes,

Corresponding Author's Institution: Edinburgh University

First Author: Niya Aleksieva

Order of Authors: Niya Aleksieva; Stuart Forbes
Biliary-derived hepatocytes in chronic liver injury: bringing new troops to the battlefield?

Niya Aleksieva¹, Stuart J Forbes*. 

¹MRC Centre for Regenerative Medicine, Scottish Centre for Regenerative Medicine, Edinburgh, UK

*Corresponding author: Stuart J. Forbes

MRC Centre for Regenerative Medicine, 5 Little France Drive, EH16 4UU, Edinburgh, United Kingdom

Telephone: 0131 651 9636

E-mail: stuart.forbes@ed.ac.uk

Word count: 1,414

Key words: liver disease, biliary-derived hepatocytes, regeneration

Conflicts of interest: The authors declare no competing personal or financial interests.

Financial support: N.A. is supported by a grant from the Wellcome Trust PhD Training Programme in Tissue Repair (R44485).

The adult liver represents a paradigm of bona fide regeneration whereby after damage it can fully restore its architecture and function. Following mild and moderate injury, this regeneration occurs via hepatocyte proliferation [1]. However, in severe chronic liver disease, the regenerative capacity of hepatocytes becomes impaired [2][3], leading to failure of the hepatocyte compartment to fully restore normal structure and function. The question of whether cells of a non-hepatocyte origin, such as biliary cells, can contribute to parenchymal repair in such a setting cannot yet be determined from human tissue samples. Animal models of liver disease have therefore been used which allow cell fate tracing to try and answer this question. However, these studies have produced conflicting and contradictory results.

Hepatocyte self-duplication has been considered to be the sole mechanism of parenchymal regeneration. Yanger et al. [4] and Schaub et al. [5] showed independently, through labelling of multiple cells types within the liver, that regeneration after injury is mediated via hepatocyte proliferation rather than from extra-hepatic sources. Font-Burgada et al. [6] further identified a population of regeneratively-proficient hepatocytes within the perportal region. These cells express a combination of hepatocyte and biliary genes and respond to injury with extensive proliferation and can repopulate the liver following injury [6].

Hepatic progenitor cells (HPCs) have also been proposed as source of hepatocyte regeneration, however there has been controversy regarding their nature. HPCs have been described as cells of biliary origin that reside in the canals of Hering in a quiescent state and during severe injury they proliferate and expand into the parenchyma in atypical structures, termed ductular reactions (DRs) [7]. Biliary derived cells contribute to parenchymal restoration, although minimally, following chronic CCL₄ treatment and partial hepatectomy [8]. However, these aforementioned injury models fail to reproduce a key characteristic feature of chronic liver disease in humans – that of significant hepatocyte senescence. Other rodent models, described below, have attempted to induce widespread
hepatocyte senescence or inhibit hepatocyte proliferation to recapitulate the replicative arrest observed in hepatocytes in human disease.

Transplanted mouse HPCs engraft and expand as hepatocytes in a mouse model in which deletion of the negative regulator of p53 – Mdm2 – leads to widespread hepatocyte senescence and parenchymal injury, thus creating a non-competitive repopulation environment [9]. Two recent studies investigated the relationship between a defect in native hepatocyte replication and the contribution of biliary-derived hepatocytes to parenchymal regeneration. Raven and Lu [10] explored multiple models combining inhibition of hepatocyte proliferation, either via Itgb1 deletion or p21 overexpression, and diet-induced liver injury models (DDC, MCD, TAA) to show that biliary-derived hepatocytes can contribute to restore a proportion of the liver parenchyma, but only when the native hepatocytes are unable to proliferate. Russel et al. [11] explored a model where native hepatocyte regeneration is impaired via β-catenin deletion and observed robust HPC-to-hepatocyte differentiation during the recovery phase from CDE-induced liver injury. Another study by Deng et al. [12] used long-term injury models (up to 52 weeks TAA and up to 24 weeks DDC), where there was a time-dependent induction of native hepatocyte senescence, combined with lineage tracing, to show that biliary-derived hepatocytes could regenerate liver parenchyma.

The present study [13] adds to the evidence for the role of biliary-derived hepatocytes in restoration of the liver parenchyma following chronic liver injury. The authors rely on mice with an inducible Osteopontin-iCreERT2 allele to label biliary cells with several different marker genes- YFP, mT/mG or confetti. They used this technique to trace biliary cells and their derivatives to define their role in liver regeneration following chronic liver injury induced by repeated CCl4 injection. It should be noted that there is some evidence in the injured liver, that OPN expression is not strictly restricted to the biliary compartment but is also present in other cell types, including damaged hepatocytes [14]. This could affect whether the genetic label is strictly related to biliary cells or could be non-specifically expressed in hepatocytes. The authors therefore performed stringent control experiments to minimise the possibility that the emergence of biliary-derived hepatocytes in their model is an artefact of the labelling system. The authors use a three-times-a-week CCl4 injection regime for up to 24 weeks that the authors describe as “severe”. This results in discrete and transient DR formation, progressive central fibrosis and gradual failure of regeneration by the hepatocyte compartment. In agreement with Raven and Lu [10] and Russel [11], the authors emphasise the requirement for inhibition of native hepatocyte proliferation to observe a significant, biliary-mediated regenerative response. Furthermore, emergence of biliary-derived hepatocytes in this model coincided with decreased proliferative activity in native hepatocytes. The authors provide data suggesting that the drop in proliferative index in native hepatocytes is due to the acquisition of a senescent phenotype. Senescent cells are known to secrete a cocktail of soluble proteins, termed senescence-associated secretory phenotype (SASP), through which they can influence the fate of surrounding tissue in a paracrine manner [15]. It is therefore tempting to hypothesise that SASP factors, secreted by senescent native hepatocytes influence the differentiation of biliary cells towards a hepatocyte phenotype. However, one cannot exclude other factors being relevant, for example proliferative hepatocytes may themselves inhibit biliary differentiation. Further studies are therefore required to determine the signals controlling the biliary-to-hepatocyte fate change.

In patients with chronic liver disease, the development of fibrosis is correlated with widespread hepatocyte senescence and persistent DR [16] [3]. The chronic CCl4 injury regime described here recapitulates the first two features; the authors report a mild and transient DR response at onset of injury that disappears by the time significant numbers of biliary-derived hepatocytes are seen. Therefore, the authors hypothesise that the biliary-derived hepatocyte patches observed in this model are a result of clonal expansion of rare differentiation events and not multiple biliary cells differentiating simultaneously. Interestingly, the experiments performed using the OPN-Cre; Rosa26RConfetti mouse suggest this holds true as no mosaicism was observed within the biliary-derived hepatocyte patches in other words the biliary derived hepatocyte patches were clonal. However, caution must be exercised when translating such findings to other models of liver disease, where injury is accompanied by florid DR and the activation of the biliary compartment diminishes only after the hepatotoxic agent is removed.
The authors investigate whether the damage response elicited by CCl4 administration differs between native and biliary-derived hepatocytes. Although both native populations exhibit similar levels of DNA damage during injury, the biliary-derived hepatocytes are shown to have less activation of pathways associated with apoptosis and cellular senescence, as well as lower levels of nuclear polyploidy, which is linked to cellular stress. During the injury recovery phase, the biliary-derived hepatocytes have a proliferative advantage over the native hepatocytes, and are able to resolve previously accumulated DNA damage, as indicated by elimination of nuclear γ-H2A foci. Therefore, the increase in number of biliary-derived hepatocytes during recovery is, again, attributed to clonal expansion and not de novo differentiation. Of note, the native hepatocytes are exposed to CCl4 for substantially longer than biliary-derived hepatocytes (which appear from week 6 of CCl4 treatment onwards), thus the longer exposure to the hepatotoxic agent can cause the native hepatocytes to be more damaged, and more likely to enter apoptosis or senescence.

The proliferative advantage of the biliary-derived hepatocytes could be considered a double-edged sword. Whereas this might be beneficial for regeneration, uncontrolled proliferation can also lead to development of cancer. Importantly, to investigate whether the biliary-derived hepatocytes possess a malignant predisposition, the authors subjected mice to 24-week CCl4 treatment to model the pre-neoplastic nodules of cirrhosis. Although a fraction of the cirrhotic nodules were composed of YFP+ biliary-derived hepatocytes or were mosaics between YFP/YFP cells, the majority of nodules were composed of YFP native hepatocytes. Exposure to the hepatocarcinogen DEN led to the development of hepatocellular carcinoma (HCC) nodules that were composed of native, YFP hepatocytes. This is in agreement with a recent study from Tummala et al. [17], where HCCs are shown to originate from damaged hepatocytes.

The present study contributes significant extra information to the knowledge of biliary-mediated hepatocyte regeneration. Considering that the only definitive treatment option for patients with end-stage chronic liver disease is transplantation and demand for donor organs far outweighs availability, describing the endogenous regenerative mechanism including biliary-mediated regeneration is important. It may be that if we can understand the molecular pathways governing the replication failure of hepatocytes and biliary-to-hepatocyte differentiation we can target these for clinical benefit. However for this to be realised clinically, a rigorous understanding of the pathways concerned is required to guarantee safety of such approaches.

References:

Figure legends

Fig. 1. Rodent models of chronic liver disease, in which the biliary-derived hepatocytes contribute to parenchymal regeneration

In chronic injury, when the native hepatocytes are able to proliferate normally, the biliary-derived hepatocytes contribute minimally to parenchymal restoration even in injury scenarios with widespread hepatocyte loss (1). In chronic injury, when the capacity of the native hepatocytes to proliferate is impaired, the biliary-derived hepatocytes contribute significantly to parenchymal regeneration (2). In prolonged chronic injury and compromised native hepatocyte proliferation, the biliary-derived hepatocytes contribute to parenchymal restoration. Importantly, the damaged, native hepatocytes are susceptible to malignant transformation (3).
1. normal hepatocyte proliferation
   chronic injury

2. impaired hepatocyte proliferation
   chronic injury

3. impaired hepatocyte proliferation
   chronic injury and cancerogenesis

- biliary cell
- healthy hepatocyte
- biliary-derived hepatocyte
- dead hepatocyte
- senescent hepatocyte
- malignant hepatocyte